AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2956958 — intervention group
Group type: COMPARATOR
Intervention: 200 mg MPA daily for surgically treated endometrial carcinoma stage I (Group II)
Number of subjects: 10
Study 2956958 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg MPA daily for metastasized breast cancer (Group III)
Number of subjects: 10
Study 2956958 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg MPA daily for metastatic breast cancer (Group IV)
Number of subjects: 10
Study 2956958 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg MPA daily for pelvic endometriosis (Group I)
Number of subjects: 10
Study 31601535 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-pull technique
Number of subjects: 110
Study 31601535 — intervention group
Group type: COMPARATOR
Intervention: Standard suction technique
Number of subjects: 110
Study 30281941 — intervention group
Group type: COMPARATOR
Intervention: 4 mL mometasone furoate-soaked biodegradable nasal dressings (BNDs) for 1 week
Number of subjects: 64
Study 30281941 — intervention group
Group type: COMPARATOR
Intervention: 4 mL mometasone furoate-soaked biodegradable nasal dressings (BNDs) for 2 weeks
Number of subjects: 64
Study 30281941 — intervention group
Group type: COMPARATOR
Intervention: 8 mL mometasone furoate-soaked biodegradable nasal dressings (BNDs) for 1 week
Number of subjects: 64
Study 30281941 — intervention group
Group type: COMPARATOR
Intervention: 8 mL mometasone furoate-soaked biodegradable nasal dressings (BNDs) for 2 weeks
Number of subjects: 64
Study 28710850 — intervention group
Group type: EXPERIMENTAL
Intervention: BAI 80 μg/day
Number of subjects: 628
Study 28710850 — intervention group
Group type: EXPERIMENTAL
Intervention: BAI 160 μg/day
Number of subjects: 628
Study 28710850 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI 80 μg/day
Number of subjects: 628
Study 28710850 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI 160 μg/day
Number of subjects: 628
Study 28710850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 628
Study 26034880 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine and Maraviroc Vaginal Rings (25 mg DPV, 100 mg MVC)
Number of subjects: 48
Study 26034880 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring (25 mg)
Number of subjects: 48
Study 26034880 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc Vaginal Ring (100 mg)
Number of subjects: 48
Study 26034880 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination Ring (DPV and MVC)
Number of subjects: 48
Study 26034880 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-drug Rings (DPV only, MVC only)
Number of subjects: 48
Study 26034880 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring
Number of subjects: 48
Study 26034880 — intervention group
Group type: COMPARATOR
Intervention: All 4 rings (DPV, MVC, DPV + MVC, Placebo)
Number of subjects: 48
Study 24204865 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment with educational handout
Number of subjects: 50
Study 24204865 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment without educational handout
Number of subjects: 50
Study 24204865 — intervention group
Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 50
Study 24204865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor-induced pain
Number of subjects: 50
Study 21806767 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/Amlodipine 150/5 mg, then titrated to 300/10 mg
Number of subjects: 443
Study 21806767 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg, then titrated to 10 mg
Number of subjects: 443
Study 21806767 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/Amlodipine
Number of subjects: 443
Study 21806767 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 443
Study 19698171 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 122
Study 19698171 — intervention group
Group type: COMPARATOR
Intervention: Supportive Listening
Number of subjects: 122
Study 16900043 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based rehabilitation course (20-week program with 19 films, written material, and Socratic dialogue)
Number of subjects: 55
Study 16900043 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based rehabilitation course
Number of subjects: 55
Study 16900043 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group (control)
Number of subjects: 55
Study 15007001 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg)
Number of subjects: 100
Study 15007001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 11545288 — intervention group
Group type: EXPERIMENTAL
Intervention: High selenium diet (297 microg/d)
Number of subjects: 11
Study 11545288 — intervention group
Group type: EXPERIMENTAL
Intervention: Low selenium diet (13 microg/d)
Number of subjects: 11
Study 8558934 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 10 micrograms/kg/day continuous i.v. infusion started 24 hours after chemotherapy completion.
Number of subjects: 26
Study 8558934 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 26
Study 8558934 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (no G-CSF)
Number of subjects: 26
Study 1921252 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mEq/d NaCl intake
Number of subjects: 27
Study 1921252 — intervention group
Group type: COMPARATOR
Intervention: 208 mEq/d NaCl intake
Number of subjects: 27
Study 6343309 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous course radiotherapy (6600 rad in 30/33 fractions over 7‐8 weeks)
Number of subjects: 141
Study 6343309 — intervention group
Group type: COMPARATOR
Intervention: Split course therapy (3000 rad in 10 fractions over 2 weeks, a three‐week rest, 3000 rad in 10 fractions over 2 weeks)
Number of subjects: 141
Study 31171491 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour ankle accelerometers
Number of subjects: 101
Study 28137295 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab or pembrolizumab (anti-PD-1 antibodies) administered according to recommended dosing schedule
Number of subjects: 0
Study 28137295 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy delivered in three fractions of 8Gy to the largest FDG-avid metastatic lesion
Number of subjects: 0
Study 25567051 — intervention group
Group type: EXPERIMENTAL
Intervention: Avocado diet (AV) including one fresh Hass avocado (136 g) per day
Number of subjects: 45
Study 25567051 — intervention group
Group type: COMPARATOR
Intervention: Moderate-fat diet (MF) mainly using high oleic acid oils
Number of subjects: 45
Study 25567051 — intervention group
Group type: COMPARATOR
Intervention: Lower-fat diet (LF: 24% fat)
Number of subjects: 45
Study 23953762 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity locomotor training on a lower-body, positive-pressure treadmill for 8 weeks
Number of subjects: 13
Study 23953762 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants (control group)
Number of subjects: 13
Study 21360405 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval running (6 × 3 min at 90% VO(2max) with active recovery at 50% VO(2max))
Number of subjects: 8
Study 21360405 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity continuous running (50 min at 70% VO(2max))
Number of subjects: 8
Study 21360405 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval running
Number of subjects: 8
Study 21360405 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity continuous running
Number of subjects: 8
Study 19561024 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow cells (BMCs) administered with each dose of cardioplegia antegradely into the coronaries
Number of subjects: 44
Study 19561024 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow cells (BMCs)
Number of subjects: 44
Study 19561024 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning (IP)
Number of subjects: 44
Study 19561024 — intervention group
Group type: COMPARATOR
Intervention: Control group (muscles harvested after CPB)
Number of subjects: 44
Study 17276669 — intervention group
Group type: EXPERIMENTAL
Intervention: Exteriorized uterine repair
Number of subjects: 206
Study 17276669 — intervention group
Group type: COMPARATOR
Intervention: In situ uterine repair
Number of subjects: 206
Study 15757268 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 12
Study 15757268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11930742 — intervention group
Group type: COMPARATOR
Intervention: No management after LC (Group A)
Number of subjects: 90
Study 11930742 — intervention group
Group type: COMPARATOR
Intervention: Absorption of residual CO2 after LC (Group B)
Number of subjects: 90
Study 11930742 — intervention group
Group type: EXPERIMENTAL
Intervention: O2 insufflation for three times followed by complete absorption of CO2 after LC (Group C)
Number of subjects: 90
Study 9391248 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose concentration at 12 mmol/l
Number of subjects: 8
Study 8009346 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and training program (Group B)
Number of subjects: 407
Study 8009346 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and training program (Group C)
Number of subjects: 407
Study 8009346 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-elastic sacro-iliac belt
Number of subjects: 407
Study 8009346 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly physical exercise before pregnancy
Number of subjects: 407
Study 8009346 — intervention group
Group type: COMPARATOR
Intervention: Group A (Control)
Number of subjects: 407
Study 2739575 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCT)
Number of subjects: 10
Study 2739575 — intervention group
Group type: COMPARATOR
Intervention: Long-chain triglycerides (LCT)
Number of subjects: 10
Study 2739575 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT
Number of subjects: 10
Study 2739575 — intervention group
Group type: COMPARATOR
Intervention: LCT
Number of subjects: 10
Study 4599671 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 27
Study 4599671 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid
Number of subjects: 27
Study 31659541 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) at a dose of 4 J/cm2
Number of subjects: 88
Study 31659541 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) at a dose of 2 J/cm2
Number of subjects: 88
Study 31659541 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 88
Study 31172967 — intervention group
Group type: EXPERIMENTAL
Intervention: MobileQuit
Number of subjects: 1271
Study 31172967 — intervention group
Group type: COMPARATOR
Intervention: QuitOnline
Number of subjects: 1271
Study 29241888 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 173
Study 25922426 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin (2 mg)
Number of subjects: 16
Study 25922426 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (20 mg)
Number of subjects: 16
Study 25922426 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 16
Study 24189570 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissonance intervention
Number of subjects: 408
Study 24189570 — intervention group
Group type: COMPARATOR
Intervention: Educational brochure control
Number of subjects: 408
Study 21382896 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (20 mg three times daily) for 6 weeks
Number of subjects: 0
Study 21382896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18027383 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 10 mg/kg
Number of subjects: 20
Study 18027383 — intervention group
Group type: COMPARATOR
Intervention: Dextrose (control)
Number of subjects: 20
Study 16830289 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha 2a 180 microg s.c. weekly plus ribavirin adjusted for patient's weight
Number of subjects: 74
Study 16830289 — intervention group
Group type: COMPARATOR
Intervention: Pegylated interferon alpha 2b 1.5 microg/kg s.c. weekly plus ribavirin adjusted for patient's weight
Number of subjects: 74
Study 14762633 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine 600 mg (single dose) on the first day, placebo on second and third days (Group CPLA)
Number of subjects: 132
Study 14762633 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 600 mg on first day and 450 mg on second and third days (Group CHLO)
Number of subjects: 132
Study 14762633 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine single dose treatment
Number of subjects: 132
Study 10865316 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic nerve decompression surgery (ONDS)
Number of subjects: 258
Study 10865316 — intervention group
Group type: COMPARATOR
Intervention: Careful follow-up
Number of subjects: 258
Study 9355955 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal laparoscopic adrenalectomy
Number of subjects: 99
Study 9355955 — intervention group
Group type: COMPARATOR
Intervention: Open adrenalectomy (control group)
Number of subjects: 99
Study 9355955 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal laparoscopic adrenalectomy (learning curve analysis)
Number of subjects: 99
Study 8105520 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms
Number of subjects: 12
Study 8105520 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 200 micrograms
Number of subjects: 12
Study 8105520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3758142 — intervention group
Group type: EXPERIMENTAL
Intervention: 32.5 mg urapidil
Number of subjects: 9
Study 3758142 — intervention group
Group type: EXPERIMENTAL
Intervention: 65 mg urapidil
Number of subjects: 9
Study 3758142 — intervention group
Group type: EXPERIMENTAL
Intervention: 130 mg urapidil
Number of subjects: 9
Study 3758142 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of urapidil
Number of subjects: 9
Study 31756281 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment for 3 months
Number of subjects: 65
Study 28924103 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (10 mg/day)
Number of subjects: 1578
Study 28924103 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1578
Study 27037630 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of fluticasone propionate and salmeterol combinations administered by oral inhalation from three different batches.
Number of subjects: 0
Study 27037630 — intervention group
Group type: EXPERIMENTAL
Intervention: Replicated batch administered in two treatment periods.
Number of subjects: 0
Study 27037630 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 24732241 — intervention group
Group type: EXPERIMENTAL
Intervention: IV endotoxin (lipopolysaccharide, 4 ng/kg)
Number of subjects: 15
Study 24732241 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial endotoxin (lipopolysaccharide, 4 ng/kg)
Number of subjects: 15
Study 23118535 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and self-efficacy intervention
Number of subjects: 4425
Study 23118535 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4425
Study 20307680 — intervention group
Group type: EXPERIMENTAL
Intervention: Pump infusion system
Number of subjects: 24
Study 20307680 — intervention group
Group type: COMPARATOR
Intervention: Gravity infusion system
Number of subjects: 24
Study 17950937 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 219
Study 17950937 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal therapy (IPT)
Number of subjects: 219
Study 16139772 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU noise and mixed-frequency white noise
Number of subjects: 5
Study 16139772 — intervention group
Group type: COMPARATOR
Intervention: ICU noise
Number of subjects: 5
Study 16139772 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 5
Study 11905302 — intervention group
Group type: EXPERIMENTAL
Intervention: AlignRite orthosis
Number of subjects: 40
Study 11905302 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolyan D‐Ring Long orthosis
Number of subjects: 40
Study 11905302 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolyan D‐Ring Short orthosis
Number of subjects: 40
Study 11905302 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made thumb hole design orthosis
Number of subjects: 40
Study 11905302 — intervention group
Group type: COMPARATOR
Intervention: Free hand
Number of subjects: 40
Study 10424184 — intervention group
Group type: EXPERIMENTAL
Intervention: One lift every 8 h
Number of subjects: 41
Study 10424184 — intervention group
Group type: EXPERIMENTAL
Intervention: One lift every 5 min
Number of subjects: 41
Study 10424184 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifting height (F-K, F-S, K-S, F-R, K-R, S-R)
Number of subjects: 41
Study 10424184 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese females
Number of subjects: 41
Study 10424184 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese males
Number of subjects: 41
Study 10424184 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese participants
Number of subjects: 41
Study 10424184 — intervention group
Group type: COMPARATOR
Intervention: Occidental participants
Number of subjects: 41
Study 7772439 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine 5 mg in 0.9% saline 5 ml i.v.
Number of subjects: 20
Study 7772439 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline 5 ml i.v. (Control)
Number of subjects: 20
Study 7772439 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 2106731 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate sodium
Number of subjects: 17
Study 2106731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 393300 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanethidine and adrenaline formulation (3.0% and 0.5%)
Number of subjects: 20
Study 393300 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanethidine and adrenaline formulation (1.0% and 0.2%)
Number of subjects: 20
Study 393300 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower concentration drops (3.0% and 0.5% or 1.0% and 0.2%)
Number of subjects: 20
Study 30730000 — intervention group
Group type: EXPERIMENTAL
Intervention: Local skin temperature at 30 °C (Cool)
Number of subjects: 10
Study 30730000 — intervention group
Group type: EXPERIMENTAL
Intervention: Local skin temperature at 36 °C (Warm)
Number of subjects: 10
Study 30730000 — intervention group
Group type: COMPARATOR
Intervention: Local skin temperature at 33 °C (Neutral)
Number of subjects: 10
Study 28875257 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (intervention) - women invited to DXA scanning based on high risk of future fracture
Number of subjects: 34229
Study 28875257 — intervention group
Group type: COMPARATOR
Intervention: Control group - women not invited to DXA scanning
Number of subjects: 34229
Study 28875257 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group - women who ticked 'not interested in DXA'
Number of subjects: 34229
Study 28875257 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group - women dropping out after primary acceptance of DXA
Number of subjects: 34229
Study 25899213 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic low back pain group
Number of subjects: 36
Study 25899213 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic low back pain group (male runners)
Number of subjects: 36
Study 25899213 — intervention group
Group type: COMPARATOR
Intervention: Healthy runners group
Number of subjects: 36
Study 23481668 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 400
Study 23481668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 22331684 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 322
Study 22331684 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 322
Study 22331684 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 322
Study 22331684 — intervention group
Group type: EXPERIMENTAL
Intervention: All diet groups
Number of subjects: 322
Study 19302641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg.kg(‐1)
Number of subjects: 80
Study 19302641 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil 20 microg.kg(‐1)
Number of subjects: 80
Study 17925866 — intervention group
Group type: EXPERIMENTAL
Intervention: PEV301 (10 microg or 50 microg)
Number of subjects: 46
Study 17925866 — intervention group
Group type: EXPERIMENTAL
Intervention: PEV302 (10 microg or 50 microg)
Number of subjects: 46
Study 17925866 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined delivery of PEV301 and PEV302
Number of subjects: 46
Study 17925866 — intervention group
Group type: EXPERIMENTAL
Intervention: PEV301 (50 microg)
Number of subjects: 46
Study 17925866 — intervention group
Group type: EXPERIMENTAL
Intervention: PEV302 (10 microg)
Number of subjects: 46
Study 17925866 — intervention group
Group type: COMPARATOR
Intervention: Control group (unmodified virosomes)
Number of subjects: 46
Study 17925866 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 46
Study 15179608 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic containing Lactobacillus and Bifidobacterium
Number of subjects: 150
Study 15179608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 11470387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation tubes
Number of subjects: 320
Study 11470387 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting (nonrandomized)
Number of subjects: 320
Study 9504725 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble oxygenator (Harvey 1700, n = 28)
Number of subjects: 62
Study 9504725 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane oxygenator (Cobe CML, n = 34)
Number of subjects: 62